Trials / Completed
CompletedNCT00790426
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
A Phase II Multi-center, Non-randomized, Open Label Study of TKI258 in FGFR3 Mutated and FGFR3 Wild Type Advanced Urothelial Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy of TKI258 in patients with advanced urothelial cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TKI258 |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2008-11-13
- Last updated
- 2020-12-19
Locations
26 sites across 8 countries: United States, Austria, Canada, Germany, Italy, Spain, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT00790426. Inclusion in this directory is not an endorsement.